{"title":"骨髓增生异常综合征的临床血液学特征和细胞遗传学--三级医疗机构的经验","authors":"R. Khanna, C. Manohar, Seemitr Verma","doi":"10.52711/0974-360x.2024.00104","DOIUrl":null,"url":null,"abstract":"Myelodysplastic syndrome forms a part of the spectrum in the process of transformation to acute leukemia. It becomes important to identify factors which can shift the balance towards acute leukemia. So, what is new? There are already a good number of prognostic factors standardized by WHO. What is less realized is this process of standardization is an ongoing one. In the present study we found three factors which had a poor prognosis. We did an in-depth study covering the clinical and morphological profile of 30 cases and the cytogenetics profile of 13/30 cases of MDS over a period of 5 years. In the present study we found 3 factors which were associated with poor survival and include polymorphic variant of chromosome 9, CD34 positive megakaryocytes in the bone marrow biopsy, and eosinophils with basophilic granules. There are occasional articles on high-level of CD34 expression on megakaryocytes associated with adverse outcome (223), but there is no literature on polymorphic variant of chromosome 9 and eosinophils with basophilic granules in association with MDS. We intend to ignite an interest on this and add to the literature.","PeriodicalId":21141,"journal":{"name":"Research Journal of Pharmacy and Technology","volume":"175 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinico-hematological Profile and Cytogenetics in Myelodysplastic Syndrome - A Tertiary Care Experience\",\"authors\":\"R. Khanna, C. Manohar, Seemitr Verma\",\"doi\":\"10.52711/0974-360x.2024.00104\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Myelodysplastic syndrome forms a part of the spectrum in the process of transformation to acute leukemia. It becomes important to identify factors which can shift the balance towards acute leukemia. So, what is new? There are already a good number of prognostic factors standardized by WHO. What is less realized is this process of standardization is an ongoing one. In the present study we found three factors which had a poor prognosis. We did an in-depth study covering the clinical and morphological profile of 30 cases and the cytogenetics profile of 13/30 cases of MDS over a period of 5 years. In the present study we found 3 factors which were associated with poor survival and include polymorphic variant of chromosome 9, CD34 positive megakaryocytes in the bone marrow biopsy, and eosinophils with basophilic granules. There are occasional articles on high-level of CD34 expression on megakaryocytes associated with adverse outcome (223), but there is no literature on polymorphic variant of chromosome 9 and eosinophils with basophilic granules in association with MDS. We intend to ignite an interest on this and add to the literature.\",\"PeriodicalId\":21141,\"journal\":{\"name\":\"Research Journal of Pharmacy and Technology\",\"volume\":\"175 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Research Journal of Pharmacy and Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52711/0974-360x.2024.00104\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research Journal of Pharmacy and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52711/0974-360x.2024.00104","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Clinico-hematological Profile and Cytogenetics in Myelodysplastic Syndrome - A Tertiary Care Experience
Myelodysplastic syndrome forms a part of the spectrum in the process of transformation to acute leukemia. It becomes important to identify factors which can shift the balance towards acute leukemia. So, what is new? There are already a good number of prognostic factors standardized by WHO. What is less realized is this process of standardization is an ongoing one. In the present study we found three factors which had a poor prognosis. We did an in-depth study covering the clinical and morphological profile of 30 cases and the cytogenetics profile of 13/30 cases of MDS over a period of 5 years. In the present study we found 3 factors which were associated with poor survival and include polymorphic variant of chromosome 9, CD34 positive megakaryocytes in the bone marrow biopsy, and eosinophils with basophilic granules. There are occasional articles on high-level of CD34 expression on megakaryocytes associated with adverse outcome (223), but there is no literature on polymorphic variant of chromosome 9 and eosinophils with basophilic granules in association with MDS. We intend to ignite an interest on this and add to the literature.
期刊介绍:
Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal, devoted to pharmaceutical sciences. The aim of RJPT is to increase the impact of pharmaceutical research both in academia and industry, with strong emphasis on quality and originality. RJPT publishes Original Research Articles, Short Communications, Review Articles in all areas of pharmaceutical sciences from the discovery of a drug up to clinical evaluation. Topics covered are: Pharmaceutics and Pharmacokinetics; Pharmaceutical chemistry including medicinal and analytical chemistry; Pharmacognosy including herbal products standardization and Phytochemistry; Pharmacology: Allied sciences including drug regulatory affairs, Pharmaceutical Marketing, Pharmaceutical Microbiology, Pharmaceutical biochemistry, Pharmaceutical Education and Hospital Pharmacy.